FDA
-
-
-
-
-
-
-
Alpha Tau reports 100% response rate in head and neck cancer combo trial
-
-
-
-
-
-
-
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
FDA approves Alpha Tau trial expansion for pancreatic cancer treatment
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)
-
-
-
-
-
-
-
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
UPDATE: Citi Starts Alpha Tau Medical Ltd. (DRTS) at Buy
-
334,870 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


